Table 1.
Clinical‐pathological characteristics of the population
| Characteristics | Number | BL1 | BL2 | IM | M | MSL | LAR | UNS | P‐valuea |
|---|---|---|---|---|---|---|---|---|---|
| (Total = 156) | (n = 23) | (n = 12) | (n = 35) | (n = 35) | (n = 11) | (n = 19) | (n = 21) | ||
| Age (Mean ± SD) | 145 | 47.7±10.4 | 59±14.6 | 50.1±12.6 | 55.2±14.2 | 53.3±10.4 | 59.1±15.6 | 51.9±14.6 | 0.0835b |
| Tumor grade | |||||||||
| ≤II | 26 | 1 (3.8) | 1 (2.1) | 3 (5.5) | 7 (5.9) | 1 (1.9) | 8 (3.1) | 5 (3.6) | |
| >II | 110 | 19 (16.2) | 10 (8.9) | 26 (23.5) | 24 (25.1) | 9 (8.1) | 8 (12.9) | 14 (15.4) | 0.0148 c |
| Unknown | 20 | ||||||||
| Tumor size (cm) | |||||||||
| ≤ 2 cm | 64 | 6 (9.3) | 6 (5.1) | 12 (14.4) | 15 (13.9) | 7 (4.6) | 9 (7.4) | 9 (9.3) | |
| > 2 cm | 74 | 14 (10.7) | 5 (5.9) | 19 (16.6) | 15 (16.1) | 3 (5.4) | 7 (8.6) | 11 (10.7) | 0.398c |
| Unknown | 18 | ||||||||
| Type histology | |||||||||
| IDC | 117 | 17 (15.9) | 6 (9.2) | 29 (26.7) | 28 (26.7) | 8 (8.4) | 13 (13.4) | 16 (16.7) | |
| Other | 23 | 2 (3.1) | 5 (1.8) | 3 (5.3) | 4 (5.3) | 2 (1.6) | 3 (2.6) | 4 (3.3) | 0.168c |
| Unknown | 16 | ||||||||
| Follow up, month (mean) | 55.8 | 50.5 | 56.6 | 55 | 48 | 65.8 | 59.8 | 62.1 | 0.562d |
| CI | 50.7–60.9 | 34.8–66.2 | 37.3–75.8 | 43.9–66.1 | 37.6–58.4 | 41.6–90.1 | 42–77.6 | 49.2–75.1 | |
| Dead event | |||||||||
| Yes | 30 | 8 (4.2) | 4 (2.3) | 9 (6.8) | 5 (6.8) | 1 (2.3) | 1 (3.4) | 2 (4.2) | 0.064c |
| No | 112 | 12 (15.8) | 7 (8.7) | 23 (25.2) | 27 (25.2) | 10 (8.7) | 15 (12.6) | 18 (15.8) | |
| Unknown | 14 | ||||||||
BL1, basal‐like 1; BL2, basal‐like 2; CI, 95% confidence interval; IDC, infiltrating ductal carcinoma; IM, immunomodulatory; LAR, luminal androgen receptor; M, mesenchymal; MSL, mesenchymal stem‐like; SD, standard deviation; UNS, undetermined.
a
Unknown data were not included for the statistical significance.
b
ANOVA test.
c
Chi‐square test P < 0.05 (in bold).
d
Kruskal–Wallis test.